Cancer Biomarkers and Oncoviruses
Academic Press Inc (Verlag)
978-0-443-30225-1 (ISBN)
The present book also covers critical analyses of cost savings in healthcare, respiratory biomarkers in viral infections, and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies. These discussions aim to provide valuable insights into how lessons from the pandemic can be applied to improve healthcare systems and response strategies for both viral infections and cancer, helping inform future health management practices.
This book is an invaluable resource for health professionals, scientists, researchers, health practitioners, students, and anyone seeking to deepen their understanding in the field of cancer and virology. It offers valuable state-of-the-art insights, incorporating the latest research and cutting-edge developments in the field.
Dr. Moulay Mustapha Ennaji, Professor in Virology and Oncology at the University of Casablanca and Director of the Quality and Medical Biotechnologies Team at Laboratory of Virology Microbiology, Hassan II University Mohammedia of Casablanca, Morocco He is currently a Professor in Virology and Oncology at the University of Casablanca, and since 2010, he has been the Director of the Quality and Medical Biotechnologies Team at the Laboratory of Virology Microbiology, Quality, Biotechnologies. He received a MSc in 1986 and a PhD in virology in 1993 from Armand Frappier Institute, University of Quebec (Canada). He has published dozens of journals articles and is an editorial board member of the journal, Infectious Agents and Cancer. Throughout his career, Dr. Ennaji has been rewarded several awards. At present, he is the vice president of the three Moroccan societies of Biosafety, Cancer, and Microbiology.
Part 1 Cancers: genetic insights, molecular mechanisms, and emerging therapies
Chapter 1: Breast cancer and new methods for treatment
Chapter 2: The role of genetic markers P53, BRCA1, and BRCA2 in breast cancer risk assessment in women
Chapter 3: MicroRNAs as key regulators of hormone dependent pathways in breast cancer
Part 2 Lung and prostate cancer: genetic abnormalities and biomarkers
Chapter 4: Genetic abnormalities of the EGFR pathway in the Middle East and North African patients with non-small cell lung cancer
Chapter 5: MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancer
Part 3 HPV and cervical cancer: screening, prevention, and molecular mechanisms
Chapter 6: Human papillomavirus infections in cervical cells for cervical cancer screening
Chapter 7: MicroRNA and human herpesvirus 8 oncovirus in prostate cancer
Part 4 Vitamin D and immune modulation in cancer
Chapter 8: Prostate cancer antigen 3 as a diagnostic, prognostic, and therapeutic biomarker in prostate cancer
Chapter 9: Interaction of the vitamin D in cancer development and progression
Part 5 Emerging therapies and biomarkers in cancer
Chapter 10: Study of the role of microRNAs in epstein barr virus induced prostate carcinogenesis
Chapter 11: Addressing the burden of human papillomavirus-related cancers in North Africa: epidemiology, sociocultural barriers and prevention strategies
Part 6 Management of the COVID-19 pandemic: lessons learned, surveillance, and respiratory biomarkers in SARS-CoV-2 pathogenesis
Chapter 12: Management of the COVID-19 pandemic in Skhirate-Temara, Morocco: lessons in preparedness, surveillance, and rapid response
Chapter 13: Respiratory biomarkers in the pathogenesis of SARS-CoV-2
Part 7 Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and therapeutic implications in cancer
Chapter 14: Oncoviruses and cancer biomarkers: current and future perspectives
Chapter 15: MicroRNAs in cancer development: biomarkers, functions and therapy
Chapter 16: Viral miRNA’s: unlocking new frontiers in virus-induced cancers
Part 8 Genetic and molecular basis of cancer
Chapter 17: Molecular alterations involved in lung cancer
Chapter 18: Oncogenic BRAF in prostate cancer: exosomes and miRNA status and implications for targeted therapy
Chapter 19: Targeted therapy in prostate and bladder cancer—role of BRAF and RAS mutations
Chapter 20: In-depth analysis of tumor markers in leukemia
Part 9 Molecular mechanisms and therapeutic implications in cancer
Chapter 21: Nasopharyngeal cancer associated with epstein barr virus
Chapter 22: Molecular mechanisms of cervical cancer
Part 10 Economic and market analysis in cancer research
Chapter 23: Critical analysis of the cost savings generated by biomarkers and oncoviruses in healthcare
Chapter 24: Market analysis of exosome technologies for the diagnosis of genitourinary cancers
Part 11 Phage therapy and immune modulation
Chapter 25: Phagotherapy: The discreet power of our immune cells
Part 12 Emerging therapies and biomarkers in cancer
Chapter 26: Mechanism of resistance to platinum salt-based chemotherapy
Chapter 27: Marine algae as a source of bioactive compounds: unlocking anticancer potential
Chapter 28: Cervical cancer: new treatment approaches using microRNA
Chapter 29: Therapeutic potential of the intratumoral microbiota in tumors
Chapter 30: Molecular biomarkers in bladder cancer: identification and clinical relevance
Chapter 31: Emerging biomarker applications for precision targeting in bladder cancer therapy
Chapter 32: Fusion gene and cancer
Chapter 33: Immunotherapy biomarkers in melanoma: fromprogrammed death-ligand 1 expression to tumor mutational burden
Chapter 34: The role of vitamin D supplementation in cancer treatment
Chapter 35: The role of vitamin D in modulating immune responses against oncoviruses human papillomavirus, Epstein–Barr virus, and human herpesvirus-8
Part 13 Epigenetics and DNA methylation in cancer
Chapter 36: Post-transcriptional epigenetic marks: DNA and microRNA methylation
Chapter 37: Epigenetic mechanism induced by human herpesvirus 8 in prostate cancer
Chapter 38: Role of methylation DNA in cell regulation
Chapter 39: DNA methylation biomarkers in colorectal cancer
Part 14 Oncoviruses and viral-associated cancers
Chapter 40: Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancers
Chapter 41: Retroviruses as biomarkers in prostate carcinoma
Chapter 42: The role of breast cancer gene 1 and breast cancer gene 2 in determining breast cancer therapy
Chapter 43: The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosis
Chapter 44: Human papillomavirus as the main cause of cervical cancer: diagnosis, treatment, and prevention
Chapter 45: Oncogenic role of proline-rich protein 11 in breast and gynecologic cancers: mechanisms, signaling pathways, and therapeutic implications
Chapter 46: MicroRNAs as biomarkers in gynecological-mammary cancers
Chapter 47: Proline-rich protein 11 as a diagnosis and prognosis biomarker in breast and cervical cancers
Chapter 48: Recent advances in therapy and biomarkers: triple negative breast cancer
Chapter 49: Recent advances in exosome-based therapies for prostate cancer: targeting oncoviral and epigenetic pathways
Chapter 50: Exosomes as carriers of viral and host biomarkers in virus-associated gynecological cancers
| Erscheinungsdatum | 20.12.2025 |
|---|---|
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 191 x 235 mm |
| Gewicht | 450 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Naturwissenschaften ► Biologie | |
| ISBN-10 | 0-443-30225-1 / 0443302251 |
| ISBN-13 | 978-0-443-30225-1 / 9780443302251 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
